The global highly potent active pharmaceutical ingredients (HPAPIs) market is set to reach nearly US$18.5bn in 2020, at a CAGR of 6.2% from 2016 to 2020, according to a new report by iHealthcareAnalyst.
The main drivers in the market are cited as patent expiry of blockbuster drugs and growing trend in pharmaceutical outsourcing.
The shift toward highly potent APIs (HPAPIs) has not only led to a pipeline of more effective medicines that require lower doses and lead to fewer side effects, but also to new manufacturing challenges.
During the past decade, the demand for HPAPIs has grown rapidly, mainly as a result of advances in clinical pharmacology and oncology research. HPAPIs drug manufacturing, storage and packaging is subject to Current Good Manufacturing Process (cGMP) regulations enforced by the US FDA, EMEA and other international regulatory agencies.
Contract manufacturing of HPAPI has been preferred over captive production due to high degree of competition and reduced profitability, geographical advantage and cost-effectiveness.
The market report provides the detailed view of the market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
The report covers APIs (biological, and chemical), Drugs (branded, generic and OTC), Manufacturing (In-house, outsourcing or contract-based), Therapeutic area (diabetes, cardiovascular, CNS, oncology, musculoskeletal drugs).
Major players operating in the HPAPIs market that are included in this report are: Alkermes, Cambrex, Dr. Reddy's Laboratories, Lonza Group, Novasep, Sandoz International, Pfizer, Sigma-Aldrich and WuXi AppTec.
For more details on the report – Highly Potent Active Pharmaceutical Ingredients Market by API (Biological, Chemical), Drugs (Branded, Generic, OTC), Manufacturing (In-House, Outsourcing or Contact-Based), Therapeutic Area (Diabetes, Cardiovascular, CNS, Oncology, Musculoskeletal Drugs) 2016-2020 – visit https://www.ihealthcareanalyst.com/report/high-potency-active-pharmaceutical-ingredient-market/